Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

122.74 -1.28 (-1.03%)
Streaming Delayed Price Updated: 12:13 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,587,901
Open 122.92
Bid (Size) 122.74 (1)
Ask (Size) 122.76 (2)
Prev. Close 124.02
Today's Range 121.29 - 123.77
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
To gain an edge, this is what you need to know today. 
Via Benzinga
AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?
Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug. 
Via InvestorPlace

Performance

YTD
+20.20%
+20.20%
1 Month
-2.94%
-2.94%
3 Month
+6.00%
+6.00%
6 Month
+21.61%
+21.61%
1 Year
+46.32%
+46.32%

More News

Read More
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Via InvestorPlace
This Is a Huge Sigh of Relief for Novo Nordisk Investors
Via The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Via Benzinga
Analyzing NYSE:NVO's Dividend Potential.
Via Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
NVO Stock Earnings: Novo Nordisk Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target
Via Investor's Business Daily
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Via Benzinga
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
Via InvestorPlace
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
Via InvestorPlace
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
Via Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
Via The Motley Fool
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
Via InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
Via Investor's Business Daily
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Viking Therapeutics Incredibly Undervalued?
Via The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
Via The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Via The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.